Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA) -- Ignore unavailable to you. Want to Upgrade?

To: Art Bechhoefer who wrote (1751)	2/11/2004 12:36:59 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 1870

Genta 4Q Loss 26c/Shr DOW JONES NEWSWIRES BERKELEY HEIGHTS, N.J. -- Genta Inc.'s (GNTA) fourth-quarter loss narrowed to $19.9 million from $29.7 million a year ago as operating costs fell by 29%. On a per-share basis, the biopharmaceutical company reported a loss of 26 cents in a press release Wednesday, compared with a year-ago loss of 40 cents. Thomson First Call projected a fourth-quarter loss of 21 cents a share, based on a survey of seven analysts. In a press release Wednesday, Genta said a write off of acquired in-process research and development reduced fourth-quarter operating costs to $22.2 million from $31.3 million a year ago. Fourth-quarter revenue more than doubled to $2.73 million from $1.32 million a year earlier, on the sales of its Ganite cancer-related hypercalcemia treatment. The drug, launched in October, relieves heightened levels of calcium in the blood. First Call projected fourth-quarter revenue of $2.07 million. Ganite, which notched sales of $1.4 million in the fourth quarter, was the company's first to be approved by the Food and Drug Administration. The drug, along with its skin cancer candidate Genasense, is leading the company's transition to a commercial business model from its prior research focus. Genta Inc. - Berkeley Heights, N.J. 4th Quar Dec. 31: 2003 2002 Revenue $2,734,000 $1,319,000 Net income a (19,923,000) (29,721,000) Avg shrs (diluted) 76,262,000 73,399,000 Shr earns Net income a (.26) (.40) Year: Revenue 6,659,000 3,559,000 Net income a (50,109,000) (74,528,000) Avg shrs (diluted) 75,093,000 70,656,000 Shr earns Net income a (.67) (1.05) Figures in parentheses are losses. a. Includes a $13.5 million write-off of acquired in-process research and development. Company Web site: genta.com